A Single and Multiple Ascending Dose Study of COR588

NCT04920903 | Completed Phase 1 FDA Drug

• 1 other identifier: COR588
• Study Type: interventional
• Target: 64
• Locations: 1 country
• Sites: 1

Brief Summary

The study is a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to assess the safety and tolerability of COR588 HCl in healthy male and female subjects.

Conditions

Healthy Volunteers

Outcome Measures

Primary Outcomes (4)

• Incidence of treatment emergent adverse events.

  Assessment of the incidence and severity of treatment-emergent adverse events.

  Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.

• Changes in chemistry lab measures (Sodium [Na], Blood Urea Nitrogen [BUN], Calcium [Ca], Total bilirubin).

  Assessment of changes in serum chemistry measures.

  Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.

• Changes in hematology lab measures (red blood cell count [RBC], hemoglobin [Hgb], hematocrit [Hct]).

  Assessment of changes in hematology measures.

  Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.

• Changes in urinalysis lab parameters (pH, specific gravity, glucose).

  Assessment of changes in urinalysis parameters.

  Through Day 8 for the single ascending dose phase and through Day 19 for the multiple ascending dose phase.

Secondary Outcomes (3)

• AUC

  To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.

• Cmax

  To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.

• Tmax

  To Day 3 for the single ascending dose phase and to Day 11 for the multiple ascending dose phase.

Study Arms (2)

COR588

EXPERIMENTAL

Drug: COR588

Placebo

PLACEBO COMPARATOR

Drug: Placebo

Interventions

COR588 DRUG

Increasing doses of COR588 will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.

COR588

Placebo DRUG

Placebo will be administered for cohorts 1-4 in the single ascending dose phase and for cohorts 1-4 in the multiple ascending dose phase.

Placebo

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female subjects between 18 to 55 years of age, inclusive (at the time of consent) for Part A;
• Body mass index between 18 and 32 kg/m2, inclusive, at screening and Day -1;
• Participants with no clinically significant abnormal screening results in the opinion of the investigator;
• All screening laboratory parameters (chemistry, hematology, coagulation, urinalysis) within normal limits or considered not clinically significant in the opinion of the investigator. If necessary, in the investigator's opinion, screening labs may be repeated once to confirm the results if error is suspected.
• Women of childbearing potential (WOCBP) must have a negative blood or urine pregnancy test within 24 hours prior to the start of investigational product and must not be breastfeeding, lactating or planning pregnancy during the study period. WOCBP must agree to use an acceptable form of contraception during the treatment period and for at least 30 days after the last dose of investigational product.
• A male subject with a female partner of childbearing potential is eligible to participate if he agrees to use acceptable contraception during the treatment period and for at least 90 days after the last dose of study treatment and refrains from donating sperm during this period;
• Agree to comply with study-specified diet and consume the high-fat breakfast in its entirety (food effect cohort) while confined in the study site;
• Provide signed informed consent prior to any study procedures commencing, understand and comply with the requirements of the study, and be able to communicate with the investigator.

You may not qualify if:

• Presence of significant neurological, cardiovascular, hematological, psychiatric, hepatic, gastrointestinal, pulmonary, endocrine, immunologic or renal disease;
• History or presence of malignancy within the past 2 years prior to Day -1 with the exception of adequately treated basal cell or squamous cell carcinoma of the skin;
• History of conditions (e.g., chronic diarrhea or prior abdominal surgery) known to interfere with the absorption, distribution, metabolism, or excretion of drugs;
• Clinically significant acute illness or infection within 14 days prior to Day -1;
• Any surgical procedure within 3 months prior to Day -1, that may interfere with the performance in the study in the judgment of the investigator;
• History or presence of cardiac abnormalities or congenital long QT syndrome;
• Subjects with a QTcF interval \>450 msec for males and \>470 msec for females at screening or Day -1;
• Any dietary restriction, intolerance, or food allergy that would prohibit the consumption of a high fat breakfast (food effect cohort only);

Sponsors & Collaborators

• Cortexyme Inc.: lead

Study Sites (1)

Nucleus Network Pty Ltd

Melbourne, Victoria, Australia

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 4, 2021
• First Posted: June 10, 2021
• Study Start: August 26, 2021
• Primary Completion: April 30, 2022
• Study Completion: April 30, 2022
• Last Updated: July 20, 2022

Record last verified: 2022-07

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)